Penile cancer

1. What the cancer is:

Penile cancer (penile carcinoma) is a malignant tumor that arises from cells of the penis — most commonly the squamous epithelial cells of the glans (head) or the foreskin (prepuce). The vast majority of penile cancers are squamous-cell carcinomas (SCC). When detected early, many penile cancers are curable. (Cancer.gov, Wikipedia)

2. Statistics and extent of the disease:

• Rarity: Penile cancer is uncommon in high-income countries. In the United States roughly ~2,000–2,200 new cases are diagnosed annually (estimates vary by year and source). Globally the disease is much more common in some low-resource regions. (Cancer.gov, Wikipedia)
• Age distribution: Incidence rises with age and most cases occur in older men (commonly in the sixth–eighth decades), though younger men can be affected. (NCBI, Cancer.gov)
• Prognosis: Prognosis depends primarily on stage at diagnosis—local disease has substantially better outcomes than disease with regional lymph-node or distant metastasis. (PMC, Cancer.gov)

3. Types of penile cancer:

Penile cancers are classified by the cell type and growth pattern. Important types include:

• Squamous cell carcinoma (SCC) — By far the most common histology (≈95% or more of penile malignancies). SCC includes several histologic variants such as usual (keratinizing) SCC, basaloid, warty (condylomatous), verrucous, sarcomatoid, and other rare patterns. Some variants (basaloid, warty) are more often HPV-related. (Wikipedia, PMC)
• Penile intraepithelial neoplasia (PeIN, carcinoma in situ): A non-invasive precursor lesion confined to the epithelium; can appear as red patches (erythroplasia) or white patches (leukoplakia) and may progress to invasive SCC if untreated. (Cancer.gov, PMC)
• Rare non-SCC tumors: Melanoma, basal-cell carcinoma, sarcomas, and adenocarcinomas are uncommon and have different management. (Wikipedia)

(Cancer.gov, NCI Visuals Online)

4. Where penile cancers typically start

Tumors most often originate on the glans or foreskin, especially under or around the prepuce; the shaft is a less common primary site. Local extension from these sites into the shaft or surrounding tissues can occur.

5. Stages

Staging uses the TNM system (Tumor, Nodes, Metastasis) and then groups stages I–IV:

• T (tumor): size/depth and local invasion (e.g., Tis = carcinoma in situ; T1 = invasion of subepithelial connective tissue; T2 = corpus spongiosum/cavernosum involvement; T4 = invasion of adjacent structures).
• N (nodes): involvement of inguinal and pelvic lymph nodes (number, size, and fixity are important prognostic factors).
• M (metastasis): distant spread (lungs, liver, bones).
• Stage I–II = generally localized to penis; Stage III = spread to regional lymph nodes; Stage IV = T4 or distant metastasis or fixed/large node disease.
• Precise staging details are used to guide treatment. (Cancer.gov, PMC)

6. Symptoms

Early lesions are often subtle. Common presentations include:

• A persistent sore, lump, or ulcer on the glans, foreskin, or shaft
• Red patches (erythroplasia) or white patches (leukoplakia)
• Bleeding, ulceration, or malodorous discharge (often beneath the foreskin)
• Pain (more often a later symptom)
• Palpable groin/inguinal lymph nodes or groin swelling (may indicate nodal spread)

Because many benign conditions (balanitis, infections, dermatologic disorders) can look similar, any persistent lesion should be evaluated and biopsied when suspicious. (MedlinePlus, Cleveland Clinic)

7. Risk factors and causes

Penile cancer arises when penile epithelial cells acquire genetic/epigenetic alterations that drive uncontrolled growth. Major risk factors include:

• Human papillomavirus (HPV): Infection with high-risk HPV types (especially HPV-16 and HPV-18) is linked to a substantial fraction of penile cancers, particularly basaloid and warty subtypes. HPV-related cancers often arise from PeIN and tend to present differently than non-HPV cancers. (NCBI, PMC)
• Phimosis and poor penile hygiene: Phimosis (inability to retract the foreskin) and chronic smegma accumulation allow chronic irritation/inflammation and are associated with higher risk. Among uncircumcised men with poor hygiene, risk is increased. (PMC, American Cancer Society)
• Lack of circumcision: Circumcision in infancy is associated with a lower lifetime risk of penile cancer; lack of neonatal circumcision is among recognized risk factors (though social, cultural, and other factors influence these findings). (American Cancer Society, PMC)
• Smoking/tobacco: Tobacco use is an independent risk factor. Smoking may interact with HPV and chronic inflammation to increase risk. (NCBI)
• Chronic dermatologic conditions: Lichen sclerosus and long-standing balanitis are associated with increased risk. (PMC)
• Immunosuppression: Men with weakened immunity (HIV infection, transplant recipients on immunosuppressants) have higher rates of HPV persistence and higher penile cancer risk. (NCBI)
• Sexual history and socioeconomic factors: Multiple sexual partners and early sexual debut (routes of HPV exposure) and lower socioeconomic status (linked to hygiene access and health care delays) are associated with higher incidence. (PMC)
• How cancers start (biology): Penile cancer arises when normal epithelial cells acquire genetic and epigenetic changes (from HPV oncoproteins, tobacco carcinogens, chronic inflammation) that drive uncontrolled growth and invasion. (PMC)

8. Prevention

Prevention strategies target modifiable risks:

• HPV vaccination: Vaccination against high-risk HPV types reduces infection and precancerous lesions and is recommended for boys and girls before sexual debut; by preventing HPV it is expected to reduce HPV-related penile cancers. (Cancer.gov)
• Good genital hygiene and prompt treatment of foreskin problems: Regular cleaning under the foreskin (in uncircumcised men) and medical attention for phimosis or chronic inflammation reduce chronic irritation. (NCBI)
• Smoking cessation: Reduces multiple cancer risks, including penile cancer. (PMC)
• Consideration of circumcision: Neonatal circumcision lowers lifetime risk; decisions should account for cultural, ethical, and medical factors.

9. Diagnosis

• Clinical examination: Careful inspection of glans, foreskin, and shaft and palpation of inguinal nodes.
• Biopsy: Tissue diagnosis (punch or excisional biopsy) is essential to confirm malignancy, determine subtype, grade, and depth of invasion.
• Imaging: Ultrasound, MRI, CT, or PET/CT are used selectively to assess local invasion, nodal status, and distant disease. MRI and ultrasound can help evaluate depth of corporal invasion.
• Nodal assessment: Because nodal status is the strongest prognostic indicator, evaluation may include sentinel-node biopsy, fine-needle aspiration of suspicious nodes, or therapeutic/diagnostic inguinal lymph node dissection (based on stage and risk). (Cancer.gov)

10. Treatment

Treatment choices depend on stage, tumour location and size, histology, patient health, and patient preferences. Major goals are cure (when possible), preservation of function and form, and palliation for advanced disease. Multimodal therapy is common.

• Local/early disease (Tis, T1, small T2):
  • Organ-sparing surgery (wide local excision, glansectomy with reconstruction) aims to remove tumor while preserving penis when possible.
  • Mohs micrographic surgery (in select centers) or CO₂ laser therapy for very superficial lesions (PeIN) or small tumors.
  • Topical therapy (e.g., 5-fluorouracil, imiquimod) or radiation (brachytherapy/external beam) are options for carcinoma in situ or small superficial tumors when surgery is not chosen. (Cancer.gov, PMC)
• Regional disease (node-positive, advanced local tumor):
  • Inguinal lymph node dissection (ILND) is often required for node-positive disease (improves survival in appropriate patients). Sentinel node biopsy helps select patients.
  • Neoadjuvant (pre-operative) or adjuvant chemotherapy (e.g., platinum-based regimens) may be used for bulky node disease. Multimodal therapy (chemotherapy ± surgery ± radiation) is recommended for advanced regional disease. (Cancer.gov)
• Metastatic (distant spread):
  • No universally curative standard exists; treatment is palliative and may include systemic chemotherapy, targeted clinical trials, and palliative surgery or radiation where needed. Immunotherapy is under investigation in trials. (Cancer.gov, Mayo Clinic Proceedings)
• Reconstruction and quality of life:
  • When resection is required, reconstructive surgery (skin grafts, flap reconstruction, penile prosthetics) and psychosocial support are important for urinary, sexual, and body-image outcomes. Multidisciplinary care (urology, medical oncology, radiation oncology, plastic surgery, psychosexual counseling) is optimal. (Cleveland Clinic, PMC)

11. Prognosis

• Early-stage penile cancer treated appropriately has a high cure rate.
• Involvement of inguinal lymph nodes is the main determinant of worse prognosis; the number, size, and fixity of nodes correlate with survival. Advanced metastatic disease carries a poor prognosis. Prompt evaluation and guideline-based node management improve outcomes. (Cancer.gov, PMC)

12. Frequently Asked Questions (FAQ’s)

• How common is penile cancer?
  • Very rare in developed countries (~2,000 U.S. cases/year); higher incidence in some low-resource regions. (Cancer.gov, Wikipedia)
• Can penile cancer be cured?
  • Yes — many early-stage cancers are curable, especially when treated before lymph nodes spread. (PMC)
• What causes penile cancer?
  • No single cause — risk factors include HPV (esp. 16/18), phimosis, poor hygiene, lack of neonatal circumcision, smoking, chronic inflammatory disorders, and immunosuppression. (NCBI, PMC)
• Does the HPV vaccine prevent penile cancer?
  • The HPV vaccine prevents infection with high-risk HPV types and reduces precancerous lesions; by preventing HPV it likely lowers penile cancer risk. Vaccination is recommended before sexual debut. (Cancer.gov)
• If I have a sore on my penis, is it cancer?
  • Most penile sores are benign (infections, trauma, dermatitis), but any persistent sore, lump, or change lasting more than a few weeks should be evaluated and biopsied if suspicious. (MedlinePlus)
• Does circumcision completely prevent penile cancer?
  • Circumcision in infancy reduces risk substantially but does not absolutely eliminate it. Many factors matter (HPV exposure, hygiene). Decisions about circumcision should consider benefits/risks and cultural context. (American Cancer Society)
• Is penile cancer contagious?
  • No — the cancer itself is not contagious. However, HPV, a risk factor for some penile cancers, is sexually transmissible. (NCBI)
• Will treatment remove the penis?
  • Not always. Many tumors can be treated with organ-preserving approaches (local excision, partial glansectomy, radiotherapy). Radical surgery (partial or total penectomy) is reserved for large or deeply invasive tumors. Reconstruction options exist. (PMC, Cleveland Clinic)
• What are the side effects of treatment?
  • Depends on treatment: surgery can affect urinary stream and sexual function; lymph node dissection risks lymphoedema and wound problems; chemo/radiation have systemic effects. Multidisciplinary care helps manage side effects. (PMC)
• How important are groin lymph nodes?
  • Very important — nodal involvement is the strongest prognostic factor and guides treatment (often requiring node dissection or systemic therapy). (Cancer.gov)
• Are there clinical trials or new treatments?
  • Yes — especially for advanced disease (new chemotherapy regimens, immunotherapy, targeted agents). Check major cancer centers or clinicaltrials.gov with your oncologist. (Mayo Clinic Proceedings, Cancer.gov)
• How do I reduce my risk personally?
  • Get HPV vaccination (if eligible), avoid tobacco, maintain genital hygiene (especially if uncircumcised), treat chronic foreskin problems early, and see a doctor for any persistent lesions. (Cancer.gov, NCBI)

CITATIONS AND SOURCES USED:

• The factual statements above are based on information from authoritative medical sources and recent reviews:
• National Cancer Institute (NCI) — Patient overview and PDQ on penile cancer. (Cancer.gov)
• NCI / Cancer.gov — news and Cancer Currents commentary on treatment patterns and outcomes. (Cancer.gov)
• Cleveland Clinic — Penile Cancer: Symptoms, Causes & Treatment. (Cleveland Clinic)
• MedlinePlus / NIH — Penile cancer entry (patient-facing). (MedlinePlus)
• PubMed / NCBI — “The Epidemiology of Penile Cancer” & contemporary reviews on risk factors. (NCBI, PubMed)
• PMC review articles: “Updates on the epidemiology and risk factors for penile cancer” and “The Diagnosis and Treatment of Penile Cancer.” (PMC)
• American Cancer Society — Risk factors and prevention (circumcision, tobacco). (American Cancer Society)
• Wikipedia — general overview (useful as a concise summary; primary sources above used for medical detail). (Wikipedia)